HealthcareServices

Global Biologics Outsourcing Market Performance Report: Global Trends 2026–2030

February 20, 2026February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics outsourcing market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Biologics Outsourcing Market in 2030?

The biologics outsourcing market has seen rapid expansion in recent years. It is forecast to grow from $22.58 billion in 2025 to $25.57 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. Historically, this market’s development was fueled by increased biologics commercialization activities, the rising capital demands for biologics facilities, the widening of biosimilar development programs, the growing intricacy of regulatory compliance, and enhanced collaboration between pharmaceutical firms and CDMOs.

The biologics outsourcing market size is projected to experience significant expansion in the coming years, anticipated to reach $42.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This growth during the projection period stems from factors such as a surge in demand for large-scale biologics manufacturing, heightened investments in facilities capable of producing multiple products, the broadening scope of cell and gene therapy outsourcing, an increased emphasis on the robustness of supply chains, and the wider implementation of digital manufacturing platforms. Key trends foreseen over the forecast period encompass an increase in strategic outsourcing for biologic production, a growing need for comprehensive end-to-end outsourcing solutions, a developing inclination towards adaptable manufacturing collaborations, the broadening of worldwide CDMO networks, and an intensified focus on optimizing both costs and risks.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

What Drivers Are Influencing Production Trends In The Biologics Outsourcing Market?

The increasing incidence of cancer is anticipated to boost the expansion of the biologics outsourcing market in the future. Cancer encompasses a wide range of diseases characterized by the uncontrolled multiplication of abnormal cells within almost any organ or tissue, which then extend beyond their typical limits and can either spread to other organs or infiltrate adjacent body parts. The outsourcing of biologics is crucial in addressing cancer by offering specialized knowledge, facilities, and structures necessary for the creation, production, and clinical provision of biologic treatments. These include monoclonal antibodies, immunotherapies, and other targeted biologics employed for the identification, therapy, and overall management of diverse cancer forms. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported 1,958,310 new cancer cases in the United States, with an estimated 609,820 cancer deaths projected for 2023. Additionally, annual new cancer diagnoses are projected to escalate to 29.5 million, and cancer-related fatalities to 16.4 million by 2040. Consequently, the growing prevalence of cancer cases is propelling the growth of the biologics outsourcing market.

Which Segments Are Gaining Traction In The Biologics Outsourcing Market?

The biologics outsourcing market covered in this report is segmented –

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products

2) By Source: Human, Microbial, Other Sources

3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications

4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization (CDMO)

Subsegments:

1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies

2) By Recombinant: Recombinant Proteins, Recombinant DNA Products

3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines

4) By Protein: Enzymes, Hormones, Cytokines

5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

What Trends Are Driving The Growth Trajectory Of The Biologics Outsourcing Market?

Leading companies in the biologics outsourcing market are focusing on developing new CDMOs to sustain their competitive standing. A contract development and manufacturing organization (CDMO) is a company that provides pharmaceutical and biotechnology firms with a variety of services related to the development and manufacturing of drugs and other therapeutic products. For instance, in October 2023, Tanvex BioPharma USA Inc., a US-based developer and manufacturer of biopharmaceuticals, launched Tanvex CDMO. This newly introduced division of the company offers end-to-end services for the development and manufacturing of biologics, catering to the needs of the biopharmaceutical industry. Located in San Diego’s Sorrento Valley biotech hub, Tanvex CDMO operates a 100,000-square-foot facility, featuring a state-of-the-art Research and Development (R&D) center, two mammalian Good Manufacturing Practice (GMP) manufacturing suites, one microbial GMP manufacturing suite, Quality Control (QC) laboratories, and a GMP warehouse. Leveraging Tanvex BioPharma USA Inc.’s proven track record, Tanvex CDMO aims to assist early-stage companies in advancing mammalian and microbial-derived biologics from conceptualization to commercialization, providing a significant boost to the field of novel biologics and biosimilars.

Who Are The Core Companies Influencing Trends In The Biologics Outsourcing Market?

Major companies operating in the biologics outsourcing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Which Regions Are Projected To Dominate The Biologics Outsourcing Market In The Coming Years?

North America was the largest region in the biologics outsourcing market in 2025. The regions covered in the biologics outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biologics Outsourcing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp

Browse Through More Reports Similar to the Global Biologics Outsourcing Market 2026, By The Business Research Company

Medical Device Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-device-outsourcing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795